ANGIOTENSINASE-INHIBITING AGENT

ANGIOTENSINASE-INHIBITING AGENT

PURPOSE:To provide the titled inhibiting agent containing a tripeptide as an active component. CONSTITUTION:The tripeptide of formula is separated and purified by subjecting swine plasma to gel-filtration, etc., with various kineds of filler (e.g., column chromatography filled with Amberlite(R)) ref...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: HASATO TADAHIKO, OTAKE NOZOMI
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator HASATO TADAHIKO
OTAKE NOZOMI
description PURPOSE:To provide the titled inhibiting agent containing a tripeptide as an active component. CONSTITUTION:The tripeptide of formula is separated and purified by subjecting swine plasma to gel-filtration, etc., with various kineds of filler (e.g., column chromatography filled with Amberlite(R)) referring angiotensinase-inhibiting activity as an index. The tripeptide is used as active component of the objective angiotensinase-inhibiting agent. The tripeptide of formula is combined with a drug-preparation carrier, a diluent or other additive to obtain a solution or an injection such as freeze-dried powder which is to be dissolved before use. It is parenteraly administered e.g. by intravenous injection. The inhibiting agent is suitable for mammals including human being producing angiotensinase in the body. Dose: 0.001-10mg/kg and 1-4 doses pser day. EFFECT:Useful as a preventive and remedy for hypertension or diagnostic agent for the disease.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JPS6354326A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JPS6354326A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JPS6354326A3</originalsourceid><addsrcrecordid>eNrjZJB39HP39A9x9Qv29HMMdtX19PPwdPIM8fRzV3B0d_UL4WFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8V4BwWbGpibGRmaOxkQoAQCsniGv</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ANGIOTENSINASE-INHIBITING AGENT</title><source>esp@cenet</source><creator>HASATO TADAHIKO ; OTAKE NOZOMI</creator><creatorcontrib>HASATO TADAHIKO ; OTAKE NOZOMI</creatorcontrib><description>PURPOSE:To provide the titled inhibiting agent containing a tripeptide as an active component. CONSTITUTION:The tripeptide of formula is separated and purified by subjecting swine plasma to gel-filtration, etc., with various kineds of filler (e.g., column chromatography filled with Amberlite(R)) referring angiotensinase-inhibiting activity as an index. The tripeptide is used as active component of the objective angiotensinase-inhibiting agent. The tripeptide of formula is combined with a drug-preparation carrier, a diluent or other additive to obtain a solution or an injection such as freeze-dried powder which is to be dissolved before use. It is parenteraly administered e.g. by intravenous injection. The inhibiting agent is suitable for mammals including human being producing angiotensinase in the body. Dose: 0.001-10mg/kg and 1-4 doses pser day. EFFECT:Useful as a preventive and remedy for hypertension or diagnostic agent for the disease.</description><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1988</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19880308&amp;DB=EPODOC&amp;CC=JP&amp;NR=S6354326A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19880308&amp;DB=EPODOC&amp;CC=JP&amp;NR=S6354326A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>HASATO TADAHIKO</creatorcontrib><creatorcontrib>OTAKE NOZOMI</creatorcontrib><title>ANGIOTENSINASE-INHIBITING AGENT</title><description>PURPOSE:To provide the titled inhibiting agent containing a tripeptide as an active component. CONSTITUTION:The tripeptide of formula is separated and purified by subjecting swine plasma to gel-filtration, etc., with various kineds of filler (e.g., column chromatography filled with Amberlite(R)) referring angiotensinase-inhibiting activity as an index. The tripeptide is used as active component of the objective angiotensinase-inhibiting agent. The tripeptide of formula is combined with a drug-preparation carrier, a diluent or other additive to obtain a solution or an injection such as freeze-dried powder which is to be dissolved before use. It is parenteraly administered e.g. by intravenous injection. The inhibiting agent is suitable for mammals including human being producing angiotensinase in the body. Dose: 0.001-10mg/kg and 1-4 doses pser day. EFFECT:Useful as a preventive and remedy for hypertension or diagnostic agent for the disease.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1988</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB39HP39A9x9Qv29HMMdtX19PPwdPIM8fRzV3B0d_UL4WFgTUvMKU7lhdLcDApuriHOHrqpBfnxqcUFicmpeakl8V4BwWbGpibGRmaOxkQoAQCsniGv</recordid><startdate>19880308</startdate><enddate>19880308</enddate><creator>HASATO TADAHIKO</creator><creator>OTAKE NOZOMI</creator><scope>EVB</scope></search><sort><creationdate>19880308</creationdate><title>ANGIOTENSINASE-INHIBITING AGENT</title><author>HASATO TADAHIKO ; OTAKE NOZOMI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JPS6354326A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1988</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>HASATO TADAHIKO</creatorcontrib><creatorcontrib>OTAKE NOZOMI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>HASATO TADAHIKO</au><au>OTAKE NOZOMI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ANGIOTENSINASE-INHIBITING AGENT</title><date>1988-03-08</date><risdate>1988</risdate><abstract>PURPOSE:To provide the titled inhibiting agent containing a tripeptide as an active component. CONSTITUTION:The tripeptide of formula is separated and purified by subjecting swine plasma to gel-filtration, etc., with various kineds of filler (e.g., column chromatography filled with Amberlite(R)) referring angiotensinase-inhibiting activity as an index. The tripeptide is used as active component of the objective angiotensinase-inhibiting agent. The tripeptide of formula is combined with a drug-preparation carrier, a diluent or other additive to obtain a solution or an injection such as freeze-dried powder which is to be dissolved before use. It is parenteraly administered e.g. by intravenous injection. The inhibiting agent is suitable for mammals including human being producing angiotensinase in the body. Dose: 0.001-10mg/kg and 1-4 doses pser day. EFFECT:Useful as a preventive and remedy for hypertension or diagnostic agent for the disease.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_JPS6354326A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title ANGIOTENSINASE-INHIBITING AGENT
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T01%3A33%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=HASATO%20TADAHIKO&rft.date=1988-03-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJPS6354326A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true